Four independent studies show rovalpituzumab tesirine ineffective against small cell lung cancer
: Blog
Ad Details
-
Ad ID: 5989
-
Added: September 7, 2021
-
Views: 6
Description
Four independent studies demonstrate that rovalpituzumab tesirine for small-cell lung cancer (SCLC) is not effective against SCLC, casting a pall over the future of the therapy and closing a door that seemed opened four years ago when the first study on the therapy was published.
Comments